Time-Dependent Efficacy of Hyperbaric Oxygen Therapy in Central Retinal Artery Occlusion.

IF 0.6 4区医学 Q4 MARINE & FRESHWATER BIOLOGY

Undersea and Hyperbaric Medicine Pub Date : 2026-03-01

Sadık Görkem Çevik, Merve Ozbek, Metehan Simsek, Gizem Taşkın, Mehmet Sait Orak, Ozgur Artunay

{"title":"Time-Dependent Efficacy of Hyperbaric Oxygen Therapy in Central Retinal Artery Occlusion.","authors":"Sadık Görkem Çevik, Merve Ozbek, Metehan Simsek, Gizem Taşkın, Mehmet Sait Orak, Ozgur Artunay","doi":"","DOIUrl":null,"url":null,"abstract":"Introduction: To determine the effect of the timing of hyperbaric oxygen (HBO₂) treatment on functional and structural outcomes in central retinal artery occlusion (CRAO).Methods: This single‑center retrospective cohort study analyzed 101 eyes with CRAO treated with HBO₂. Eyes were stratified by symptom‑to‑treatment interval: ≤12 hours (Group 1), 12-24 hours (Group 2), 24-36 hours (Group 3), and >36 hours (Group 4). Best‑corrected visual acuity (BCVA-logMAR), central macular thickness (CMT), and inner retinal hyperreflective band thickness (IRHBT) were recorded at presentation, week 1, and month 6.Results: Presentation BCVA was 2.16 ± 1.04, improving to 1.77 ± 1.02 at month 6 (p = 0.03). The mean BCVA gain was greatest in Group 1: -0.85 ± 0.96, and declined markedly with delayed treatment initiation (Group 2: -0.48 ± 1.38; Group 3: -0.10 ± 1.50; Group 4: -0.08 ± 1.77). In Group 1, the mean BCVA improved significantly from 2.04 ± 0.78 logMAR at presentation to 1.19 ± 0.56 logMAR at the 6-month follow-up (p = 0.02). Early treatment was also associated with more pronounced reductions in CMT and IRHBT, whereas anatomical changes were negligible when therapy was initiated beyond 24 hours. Baseline CMT and IRHBT showed modest but significant correlations with final BCVA (r = 0.37, p = 0.03 , and r=0.34, p=0.04, respectively).Discussion: HBO₂ provides a significant, time-sensitive benefit for CRAO; initiating treatment within 12-24 hours maximizes recovery and retinal remodeling, validating HBO₂ as a critical adjunct and necessitating rapid triage in ophthalmic emergencies.","PeriodicalId":49396,"journal":{"name":"Undersea and Hyperbaric Medicine","volume":"53 3","pages":"471-480"},"PeriodicalIF":0.6000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Undersea and Hyperbaric Medicine","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MARINE & FRESHWATER BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: To determine the effect of the timing of hyperbaric oxygen (HBO₂) treatment on functional and structural outcomes in central retinal artery occlusion (CRAO).

Methods: This single‑center retrospective cohort study analyzed 101 eyes with CRAO treated with HBO₂. Eyes were stratified by symptom‑to‑treatment interval: ≤12 hours (Group 1), 12-24 hours (Group 2), 24-36 hours (Group 3), and >36 hours (Group 4). Best‑corrected visual acuity (BCVA-logMAR), central macular thickness (CMT), and inner retinal hyperreflective band thickness (IRHBT) were recorded at presentation, week 1, and month 6.

Results: Presentation BCVA was 2.16 ± 1.04, improving to 1.77 ± 1.02 at month 6 (p = 0.03). The mean BCVA gain was greatest in Group 1: -0.85 ± 0.96, and declined markedly with delayed treatment initiation (Group 2: -0.48 ± 1.38; Group 3: -0.10 ± 1.50; Group 4: -0.08 ± 1.77). In Group 1, the mean BCVA improved significantly from 2.04 ± 0.78 logMAR at presentation to 1.19 ± 0.56 logMAR at the 6-month follow-up (p = 0.02). Early treatment was also associated with more pronounced reductions in CMT and IRHBT, whereas anatomical changes were negligible when therapy was initiated beyond 24 hours. Baseline CMT and IRHBT showed modest but significant correlations with final BCVA (r = 0.37, p = 0.03 , and r=0.34, p=0.04, respectively).

Discussion: HBO₂ provides a significant, time-sensitive benefit for CRAO; initiating treatment within 12-24 hours maximizes recovery and retinal remodeling, validating HBO₂ as a critical adjunct and necessitating rapid triage in ophthalmic emergencies.

本刊更多论文

高压氧治疗视网膜中央动脉闭塞的时间依赖性疗效。

目的：确定高压氧（HBO₂）治疗时机对视网膜中央动脉闭塞（CRAO）的功能和结构结局的影响。方法：本研究为单中心回顾性队列研究，分析了101只采用HBO 2治疗的cro。根据症状到治疗的时间间隔对眼睛进行分层：≤12小时（第1组）、12-24小时（第2组）、24-36小时（第3组）和bb0 -36小时（第4组）。最佳矫正视力（BCVA-logMAR）、中央黄斑厚度（CMT）和视网膜内高反射带厚度（IRHBT）分别于就诊时、第1周和第6个月进行记录。结果：首发BCVA为2.16±1.04，第6个月为1.77±1.02 （p = 0.03）。组1的平均BCVA增益最大，为-0.85±0.96，随着治疗开始时间的推迟，BCVA增益显著下降（组2:-0.48±1.38；组3:-0.10±1.50；组4:-0.08±1.77）。在组1中，平均BCVA从出现时的2.04±0.78 logMAR显著改善到6个月随访时的1.19±0.56 logMAR （p = 0.02）。早期治疗也与CMT和IRHBT的显著降低相关，而当治疗超过24小时时，解剖变化可以忽略不计。基线CMT和IRHBT与最终BCVA有适度但显著的相关性（分别为r= 0.37, p= 0.03和r=0.34, p=0.04）。讨论：HBO 2为CRAO提供了显著的、时间敏感的好处；在12-24小时内开始治疗可以最大限度地恢复和重塑视网膜，验证HBO 2作为关键辅助手段，并需要在眼科紧急情况下进行快速分诊。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Undersea and Hyperbaric Medicine 医学-海洋与淡水生物学

CiteScore

1.60

自引率

11.10%

发文量

审稿时长

>12 weeks

期刊介绍： Undersea and Hyperbaric Medicine Journal accepts manuscripts for publication that are related to the areas of diving research and physiology, hyperbaric medicine and oxygen therapy, submarine medicine, naval medicine and clinical research related to the above topics. To be considered for UHM scientific papers must deal with significant and new research in an area related to biological, physical and clinical phenomena related to the above environments.